BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

126 related articles for article (PubMed ID: 37956529)

  • 1. Risk factors for hypogammaglobulinemia and association with relapse and severe infections in ANCA-associated vasculitis: A cohort study.
    Liberatore J; Nguyen Y; Hadjadj J; Cohen P; Mouthon L; Puéchal X; Guillevin L; Terrier B
    J Autoimmun; 2024 Jan; 142():103130. PubMed ID: 37956529
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Predictors of hypogammaglobulinemia in ANCA-associated vasculitis after a rituximab-based induction: a multicentre study.
    Podestà MA; Mescia F; Ricchiuto A; Smith R; Tedesco M; Cassia MA; Holle J; Sinico RA; Bruchfeld A; Gunnarsson I; Ohlsson S; Baslund B; Hruskova Z; Tesar V; Sabiu G; Gallieni M; Cid MC; Vaglio A; Harper L; Cozzolino M; Scolari F; Jayne D; Alberici F
    Rheumatology (Oxford); 2023 Aug; 62(8):2850-2854. PubMed ID: 36562566
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Rituximab for remission induction in elderly patients with ANCA-associated vasculitis.
    Timlin H; Lee SM; Manno RL; Seo P; Geetha D
    Semin Arthritis Rheum; 2015 Aug; 45(1):67-9. PubMed ID: 25796088
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Long-term follow-up of patients who received repeat-dose rituximab as maintenance therapy for ANCA-associated vasculitis.
    Alberici F; Smith RM; Jones RB; Roberts DM; Willcocks LC; Chaudhry A; Smith KG; Jayne DR
    Rheumatology (Oxford); 2015 Jul; 54(7):1153-60. PubMed ID: 25477054
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Long-term maintenance rituximab for ANCA-associated vasculitis: relapse and infection prediction models.
    McClure ME; Zhu Y; Smith RM; Gopaluni S; Tieu J; Pope T; Kristensen KE; Jayne DRW; Barrett J; Jones RB
    Rheumatology (Oxford); 2021 Mar; 60(3):1491-1501. PubMed ID: 33141217
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Evaluation of Rituximab for Induction and Maintenance Therapy in Patients 75 Years and Older With Antineutrophil Cytoplasmic Antibody-Associated Vasculitis.
    Thietart S; Karras A; Augusto JF; Philipponnet C; Carron PL; Delbrel X; Mesbah R; Blaison G; Duffau P; El Karoui K; Smets P; London J; Mouthon L; Guillevin L; Terrier B; Puéchal X;
    JAMA Netw Open; 2022 Jul; 5(7):e2220925. PubMed ID: 35802372
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Association of Serum Calprotectin (S100A8/A9) Level With Disease Relapse in Proteinase 3-Antineutrophil Cytoplasmic Antibody-Associated Vasculitis.
    Pepper RJ; Draibe JB; Caplin B; Fervenza FC; Hoffman GS; Kallenberg CG; Langford CA; Monach PA; Seo P; Spiera R; William St Clair E; Tchao NK; Stone JH; Specks U; Merkel PA; Salama AD;
    Arthritis Rheumatol; 2017 Jan; 69(1):185-193. PubMed ID: 27428710
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Efficacy and Safety of Belimumab and Azathioprine for Maintenance of Remission in Antineutrophil Cytoplasmic Antibody-Associated Vasculitis: A Randomized Controlled Study.
    Jayne D; Blockmans D; Luqmani R; Moiseev S; Ji B; Green Y; Hall L; Roth D; Henderson RB; Merkel PA;
    Arthritis Rheumatol; 2019 Jun; 71(6):952-963. PubMed ID: 30666823
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Effect of Continuous B Cell Depletion With Rituximab on Pathogenic Autoantibodies and Total IgG Levels in Antineutrophil Cytoplasmic Antibody-Associated Vasculitis.
    Cortazar FB; Pendergraft WF; Wenger J; Owens CT; Laliberte K; Niles JL
    Arthritis Rheumatol; 2017 May; 69(5):1045-1053. PubMed ID: 28029751
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Extended versus standard azathioprine maintenance therapy in newly diagnosed proteinase-3 anti-neutrophil cytoplasmic antibody-associated vasculitis patients who remain cytoplasmic anti-neutrophil cytoplasmic antibody-positive after induction of remission: a randomized clinical trial.
    Sanders JS; de Joode AA; DeSevaux RG; Broekroelofs J; Voskuyl AE; van Paassen P; Kallenberg CG; Tervaert JW; Stegeman CA
    Nephrol Dial Transplant; 2016 Sep; 31(9):1453-9. PubMed ID: 27242368
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Rituximab resistance at 3months of induction therapy in newly diagnosed or relapsing ANCA-associated vasculitis: A French multicentre retrospective study in 116 patients.
    Machet T; Quémeneur T; Ledoult E; Mesbah R; Lebas C; Hachulla E; Pokeerbux MR
    Joint Bone Spine; 2023 Sep; 90(5):105591. PubMed ID: 37230162
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Efficacy of Rituximab and Plasma Exchange in Antineutrophil Cytoplasmic Antibody-Associated Vasculitis with Severe Kidney Disease.
    Casal Moura M; Irazabal MV; Eirin A; Zand L; Sethi S; Borah BJ; Winters JL; Moriarty JP; Cartin-Ceba R; Berti A; Baqir M; Thompson GE; Makol A; Warrington KJ; Thao V; Specks U; Fervenza FC
    J Am Soc Nephrol; 2020 Nov; 31(11):2688-2704. PubMed ID: 32826324
    [TBL] [Abstract][Full Text] [Related]  

  • 13. B-cell treatment in ANCA-associated vasculitis.
    Karras A; Lazareth H; Chauvet S
    Rheumatology (Oxford); 2020 May; 59(Suppl 3):iii68-iii73. PubMed ID: 32348514
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Rituximab-associated hypogammaglobulinemia in autoimmune rheumatic diseases: a single-center retrospective cohort study.
    Wade SD; Kyttaris VC
    Rheumatol Int; 2021 Jun; 41(6):1115-1124. PubMed ID: 33811499
    [TBL] [Abstract][Full Text] [Related]  

  • 15. The association of serum interleukin-6 levels with clinical outcomes in antineutrophil cytoplasmic antibody-associated vasculitis.
    Berti A; Warner R; Johnson K; Cornec D; Schroeder DR; Kabat BF; Langford CA; Kallenberg CGM; Seo P; Spiera RF; St Clair EW; Fervenza FC; Stone JH; Monach PA; Specks U; Merkel PA;
    J Autoimmun; 2019 Dec; 105():102302. PubMed ID: 31320177
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Rituximab as maintenance therapy for ANCA-associated vasculitides: pooled analysis and long-term outcome of 277 patients included in the MAINRITSAN trials.
    Delestre F; Charles P; Karras A; Pagnoux C; Néel A; Cohen P; Aumaître O; Faguer S; Gobert P; Maurier F; Samson M; Godmer P; Bonnotte B; Cottin V; Hanrotel-Saliou C; Le Gallou T; Carron PL; Desmurs-Clavel H; Direz G; Jourde-Chiche N; Lifermann F; Martin-Silva N; Pugnet G; Quéméneur T; Matignon M; Benhamou Y; Daugas E; Lazaro E; Limal N; Ducret M; Huart A; Viallard JF; Hachulla E; Perrodeau E; Puechal X; Guillevin L; Porcher R; Terrier B;
    Ann Rheum Dis; 2024 Jan; 83(2):233-241. PubMed ID: 37918894
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Long-term efficacy of remission-maintenance regimens for ANCA-associated vasculitides.
    Terrier B; Pagnoux C; Perrodeau É; Karras A; Khouatra C; Aumaître O; Cohen P; Decaux O; Desmurs-Clavel H; Maurier F; Gobert P; Quémeneur T; Blanchard-Delaunay C; Bonnotte B; Carron PL; Daugas E; Ducret M; Godmer P; Hamidou M; Lidove O; Limal N; Puéchal X; Mouthon L; Ravaud P; Guillevin L;
    Ann Rheum Dis; 2018 Aug; 77(8):1150-1156. PubMed ID: 29724729
    [TBL] [Abstract][Full Text] [Related]  

  • 18. PR3-ANCAs predict relapses in ANCA-associated vasculitis patients after rituximab.
    van Dam LS; Dirikgil E; Bredewold EW; Ray A; Bakker JA; van Kooten C; Rabelink TJ; Teng YKO
    Nephrol Dial Transplant; 2021 Jul; 36(8):1408-1417. PubMed ID: 32601673
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Rituximab prescription patterns and efficacy in the induction treatment of ANCA-Associated Vasculitis in a Belgian multicenter cohort.
    Chasseur P; Blockmans D; von Frenckell C; Nicolas JB; Regniers C; Vandergheynst F
    Acta Clin Belg; 2020 Jun; 75(3):163-169. PubMed ID: 30767717
    [No Abstract]   [Full Text] [Related]  

  • 20. Severe infections in patients with ANCA-associated vasculitis treated with rituximab.
    Segelmark L; Flores-Suárez L; Mohammad A
    Rheumatology (Oxford); 2021 Dec; 61(1):205-212. PubMed ID: 33757116
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.